A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts

Multinuclear platinum compounds were rationally designed to bind to DNA in a different manner from that of cisplatin and its mononuclear analogues. A triplatinum compound of the series (BBR 3464) was selected for preclinical development, since, in spite of its charged nature, it was very potent as c...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Pratesi, G, Perego, P, Polizzi, D, Righetti, S C, Supino, R, Caserini, C, Manzotti, C, Giuliani, F C, Pezzoni, G, Tognella, S, Spinelli, S, Farrell, N, Zunino, F
Format: Artigo
Język:Inglês
Wydane: Nature Publishing Group 1999
Hasła przedmiotowe:
Regular Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2363141/
https://ncbi.nlm.nih.gov/pubmed/10471039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6690620
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy